Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer.
Zsuzsanna ValkoZsolt MegyesfalviAnna SchwendenweinChristian LangSandor PakuNandor BaranyBence FerenczAnita Horvath-RozsasIldiko KovacsErzsebet SchleglVeronika PozonecKristiina BoettigerMelinda RezeliGyorgy Marko-VargaFerenc Renyi-VamosMir Alireza HodaThomas KlikovitsKonrad HoetzeneckerMichael GruschViktoria LaszloBalázs DomeKarin SchelchPublished in: British journal of cancer (2023)
The current study reveals the subtype specificity of BCL-2 expression and sheds light on the mechanism of venetoclax resistance in SCLC. Additionally, we provide preclinical evidence that combined BCL-2 and MCL-1 targeting is an effective approach to overcome venetoclax resistance in high BCL-2-expressing SCLCs with intact BAX.